BUZZ-Vigil Neuroscience rises on early-stage Alzheimer's drug trial data

Reuters
01-23
BUZZ-Vigil Neuroscience rises on early-stage Alzheimer's drug trial data

** Shares of drug developer Vigil Neuroscience VIGL.O rise 10% to $2.25

** VIGL says its experimental Alzheimer's drug, VG-3927, reduced key biomarker sTREM2 by up to 50% in cerebral spinal fluid in early-stage trial

** Reduction in sTREM2 levels is expected to help slow progression of Alzheimer's disease, as higher levels suggest brain inflammation

** Co says VG-3927 was well-tolerated and has favorable pharmacokinetic and pharmacodynamic profile in the trial

** VIGL plans to advance into mid-stage trial in Q3 2025

** 8 of 9 brokerages rate stock "buy" or higher and 1 "sell"; their median PT is $16.50 - data compiled by LSEG

** VIGL fell ~51% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10